The EPS beat is mechanical on a tiny base and irrelevant for a clinical-stage biotech. The key catalysts are FDA feedback on VT-1953 Orphan Drug Designation and whether the JAK inhibitor in-license progresses to clinical milestones. With only $8.8M cash and $1.1M quarterly burn, watch for warrant exercise or future dilutive offerings if pipeline milestones slip. The revenue collapse is not material for the thesis — pipeline milestones are the only driver for HIND.
Price Chart
Executive Summary
Vyome Holdings reported Q1 2026 EPS of -$0.15, beating the consensus estimate of -$0.19 by 21%, but revenue collapsed 84% YoY to $31.6K from $198.6K. The company highlighted FDA filings for Orphan Drug Designation on VT-1953, an in-licensing deal for JAK inhibitors with Impetis Biosciences (TATA Enterprise), and a $5.29M equity raise at a 59% premium — but the revenue decline and cash burn dominate the outlook for a $16M market-cap clinical-stage biotech.
Key Financial Metrics
Key Facts
- Revenue fell 84% YoY to $31.6K (Q1 2026) from $198.6K (Q1 2025), though revenue remains immaterial for a clinical-stage biotech
- EPS of -$0.15 beat consensus of -$0.19 by 21.1%
- Net loss widened to -$985.5K from -$294.0K YoY, driven by operating expenses tripling to $1.15M
- Cash & equivalents: $8.8M as of March 31, 2026, up from $5.0M at Dec 2025 after a $5.29M equity raise
- Filed Orphan Drug Designation application with FDA for VT-1953 and in-licensed two JAK inhibitor assets from Impetis Biosciences (TATA) with payments at commercialization
- Clean capital structure maintained — no debt, preferred, or toxic instruments
Financial Impact
Revenue declined ~84% YoY to $31.6K; net loss widened to -$985.5K; cash burn rate of ~$1.1M/quarter ($8.8M cash = ~8 quarters runway)
Risk Factors
- VT-1953 Orphan Drug Designation may be denied or delayed
- Cash runway extends only through ~8 quarters at current burn; clinical setbacks would force dilutive financing
- Revenue disappearance to $31.6K reduces credibility of any near-term commercialization revenue
- Post-market close May 28 — elevated after-hours volatility risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-062458 |
| Document: ea0292643-8k_vyome.htm | 0001213900-26-062458 |
| Document: 0001213900-26-062458-index-headers.html | 0001213900-26-062458 |
| Document: 0001213900-26-062458-index.html | 0001213900-26-062458 |
| Document: 0001213900-26-062458.txt | 0001213900-26-062458 |
| 8-K Data (Synthetic) | 0001213900-26-062458 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 29, 2026 21w ago | 8-K | $2.34 $2.24 | ▲ +4.19% | ▲ +5.37% | $1.71 (+26.92%) |
Feb 25, 2026 34w ago | 8-K | $3.36 $2.23 | ▼ −33.63% | ▼ −41.38% | $1.71 (−49.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers